期刊文献+

阿普斯特合成路线图解

Graphical Synthetic Routes of Apremilast
下载PDF
导出
摘要 阿普斯特是美国Celgene公司研发的一种口服类的选择性磷酸二酯酶4(PDE4)抑制剂,通过调节胞内促炎与抗炎因子,抑制参与银屑病发病机制中的多个炎症的活性,从而有效治疗银屑病。阿普斯特分别获得FDA、EMA监管机构批准用于活动性银屑病关节炎和中度至重度斑块型银屑病的治疗。因此对其研究具有重要的意义。本文对阿普斯特的合成路线进行了总结,利用图解的方式对阿普斯特合成路线进行了综述和评价。 Apremilast,which was developed by Celgene Corporation Company,is the first oral inhibitor of phosphodiesterase 4.It is effective in the treatment of psoriasis by regulating intracellular pro-inflammatory and antiinflammatory factors and inhibiting the activity of multiple inflammatory factors involved in the pathogenesis of psoriasis.It has been approved by FDA and EMA for the treatment of active psoriatic arthritis(PsA)and plaque psoriasis who are candidates for phototherapy or systemic therapy.The study for its synthesis has important significance.In this article,we conclude its synthetic route,graphic method was used to review and evaluate its synthetic process.
作者 叶琼仙 罗统有 邓吉聪 谭志聪 Ye Qiong-xian;Luo Tong-you;Deng Ji-cong;Tan Zhi-cong(Guangdong Zhongsheng Pharmaceutical Co.,Ltd.,Dongguan Guangdong 523320,China;Guangdong Xianqiang Pharmaceutical Co.,Ltd.,Guangzhou Guangdong 510900,China)
出处 《江西化工》 CAS 2024年第1期12-15,共4页 Jiangxi Chemical Industry
关键词 阿普斯特 合成路线 银屑病 磷酸二酯酶4 apremilast synthetic route psoriasis phosphodiesterase 4
  • 相关文献

参考文献2

二级参考文献31

  • 1Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis [J]. Biochem Pharmacol, 2012, 83: 1583-1590.
  • 2Papp K, Cather J C, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial [J]. Lancet, 2012, 380(9843): 738-746.
  • 3Schafer P H, Parton A, Gandhi A K, et al. Apremilast, a cAMP phosphodiesterase4 inhibitor, demonstrates anti- inflammatory activity in vitro and in a model of psoriasis [J]. BrJPharmacol, 2010, 159: 842-855.
  • 4McCann F E, Palfreeman A C, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis [J]. Arthritis Res Ther, 2010, 12(3): R107.
  • 5Gottlieb A B, Strober B, Krueger J G, et al. An open-label, single-arm pilot study in patients withsevere plaque-type psoriasis treated with an oral antiinflammatory agent, apremilast [J]. Curr Med Res Opin, 2008, 24(5): ! 529-1538.
  • 6Capone L, Rogovitz A, Gandhi A K, et al. Antiinflammatory activity of apremilast against T cells, chondrocytes, andrheumatoid arthritis synovial fibroblasts in vitro [R]. Chicago: annual scientific meeting of the American College of Rheumatology, 2011.
  • 7Serezani C H, Ballinger M N, Aronoff D M, et al. Cyclic AMP: master regulator of innate immune cell function [J]. Am J Respir Cell Mol Biol, 2008, 39(2): 127-132.
  • 8Schett G, Sloan V S, Stevens R M, et al. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases [J]. Ther Adv Musculoskelet Dis, 2010, 2(5): 271-278.
  • 9Man H W, Schafer P, Wong L M, et al. Discovery of (S)-N- [2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]- 1,3-dioxo-2,3-dihydro-lH-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis fhctor-ct inhibitor [J]. J Med Chem, 2009, 52(6): 1522-1524.
  • 10Schafer P H, Patton A, Gandhi A K, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti- inflammatory activity in vitro and in a model of psoriasis [J]. BrJPharmacol, 2010, 159(4): 842-855.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部